| abstract |
A pyrazolopyrimidine derivative represented by the general formula (I) and a pharmaceutically acceptable salt thereof exhibits excellent MAPKAP-K2 inhibitory activity. A pharmaceutical agent comprising the compound as the active ingredient is expected to be useful for the treatment of MAPKAP-K2-mediated disorders including inflammatory disorders, autoimmune disease, destructive bone disorders, cancer and/or tumor growth. |